To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

LUNG CANCER

Experimental lung cancer drug promising

By Christine Blank
AstraZeneca recently released positive new data on its experimental non-small cell lung cancer (NSCLC) drug, AZD9291 (osimertinib). Study details

Risk of neutropenia prompts new monitoring for antipsychotic drug

By Julia Talsma
A new REMS Program has been established for clozapine, an atypical antipsychotic for treatment-resistant schizophrenia, due to the continued risk of severe neutropenia, which can be life-threatening. REMS Program reliability

CONTINUING EDUCATION

Primer on inhalers and nebulizers

This month's CE activity is part of the CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to discuss the various types of inhaled devices and educate pharmacists on the techniques for correct device use.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT33-FTX29.

The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php.
All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce

EDITOR'S PICK

Injectable cholesterol-lowering drug has positive initial results after first test

by Christine Blank
Alnylam Pharmaceuticals and The Medicines Company reported positive initial results from their ongoing phase 1 clinical trial with their injectable cholesterol-lowing drug, ALSN-PCSsc, at the ESC Congress 2015. Details

September 30, 2015

Related Articles

• Diabetic non-smokers taking metformin have lower lung cancer risk

• Children's use of antipsychotics may increase risk of diabetes

Sponsored links

A Systematic Approach to Weight Loss and Disease Management

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters